These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 12466002)

  • 1. Etoricoxib.
    Cochrane DJ; Jarvis B; Keating GM
    Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
    Patrignani P; Capone ML; Tacconelli S
    Expert Opin Pharmacother; 2003 Feb; 4(2):265-84. PubMed ID: 12562317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
    J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study.
    Malmstrom K; Sapre A; Couglin H; Agrawal NG; Mazenko RS; Fricke JR
    Clin Ther; 2004 May; 26(5):667-79. PubMed ID: 15220011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Etoricoxib (Arcoxia)].
    Leclercq P; Malaise MG
    Rev Med Liege; 2004 May; 59(5):345-9. PubMed ID: 15270001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.
    Malmstrom K; Kotey P; Coughlin H; Desjardins PJ
    Clin J Pain; 2004; 20(3):147-55. PubMed ID: 15100590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
    Hunt RH; Harper S; Callegari P; Yu C; Quan H; Evans J; James C; Bowen B; Rashid F
    Aliment Pharmacol Ther; 2003 Jan; 17(2):201-10. PubMed ID: 12534404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
    Fenton C; Keating GM; Wagstaff AJ
    Drugs; 2004; 64(11):1231-61. PubMed ID: 15161329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoricoxib.
    Matsumoto AK; Cavanaugh PF
    Drugs Today (Barc); 2004 May; 40(5):395-414. PubMed ID: 15319795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.
    Birbara CA; Puopolo AD; Munoz DR; Sheldon EA; Mangione A; Bohidar NR; Geba GP;
    J Pain; 2003 Aug; 4(6):307-15. PubMed ID: 14622687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The second generation of COX-2 inhibitors: what advantages do the newest offer?
    Stichtenoth DO; Frölich JC
    Drugs; 2003; 63(1):33-45. PubMed ID: 12487621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
    Leung AT; Malmstrom K; Gallacher AE; Sarembock B; Poor G; Beaulieu A; Castro R; Sanchez M; Detora LM; Ng J
    Curr Med Res Opin; 2002; 18(2):49-58. PubMed ID: 12017209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.